Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

ensartinib

ensartinib is a alk tyrosine kinase receptor inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 1
Drug details — ensartinib
Class
—
Route
—
Patents
0
Programs
3
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

ensartinib is a alk tyrosine kinase receptor inhibitor.

Key facts

INN ensartinib
Mechanism ALK tyrosine kinase receptor inhibitor
Target ALK tyrosine kinase receptor

Mechanism of action

ALK tyrosine kinase receptor inhibitor

Primary target: ALK tyrosine kinase receptor

Approval history

Authority Status Date
NMPA clinical trials —

Recent coverage

View all news
Ensartinib Phase 3 Results: Market Impact in ALK-Positive NSCLC US
High impact AnalysisOncologyApr 26, 2026

Ensartinib Phase 3 Results: Market Impact in ALK-Positive NSCLC US

FDA · Oncology · 5 min

The Phase 3 results of Ensartinib demonstrate promising efficacy in ALK-positive NSCLC, potentially reshaping treatment options and market dynamics in the US.

Daniel Brooks

Pipeline programs

Search pipeline
  1. Ensartinib Phase 2 · Chinese Academy of · Non-Small Cell Lung Cancer
  2. Ensartinib Phase 2 · First People's Hospital · Solid Tumors
  3. Ensartinib group Phase 2 · Chinese Academy of · NSCLC

Related & competitor drugs

Browse all drugs
  1. brigatinib Antineoplastic and immunomodulating agents (L01)
  2. alectinib hydrochloride EML4-ALK
  3. ceritinib Antineoplastic and immunomodulating agents (L01)
  4. crizotinib Antineoplastic and immunomodulating agents (L01)
  5. entrectinib Antineoplastic and immunomodulating agents (L01)
  6. lorlatinib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is ensartinib?

ensartinib is a alk tyrosine kinase receptor inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.